{
    "organizations": [],
    "uuid": "5dab567d1cc19491878693249e0d1b0f952ee109",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/16/globe-newswire-newlink-genetics-to-host-its-fourth-quarter-and-year-end-2017-financial-results-conference-call-on-march-1-2018.html",
    "ord_in_thread": 0,
    "title": "NewLink Genetics to Host Its Fourth Quarter and Year End 2017 Financial Results Conference Call on March 1, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "AMES, Iowa, Feb. 16, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will release its fourth quarter and year end 2017 financial results on Thursday, March 1, 2018. The company has scheduled a conference call for 4:30 PM ET the same day to discuss the results and to give an update on clinical and business development activities.\nNewLink Genetics' senior management team will host the conference call, which will be open to all listeners. There will also be a question and answer session following the prepared remarks.\nAccess to the live call is available by dialing (855) 469-0612 (U.S.) or (484) 756-4268 (international) five minutes prior to the start of the call. The conference call will be webcast live and a link can be accessed through the NewLink Genetics website at https://edge.media-server.com/m6/p/8rng5oig . A replay of the call will be available for two weeks from the date of the call and can be accessed by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and using the passcode 9466627.\nAbout NewLink Genetics Corporation\nNewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. Indoximod, the companyâ€™s leading IDO inhibitor, is being evaluated in combination with treatment regimens including anti-PD-1/PD-L1 agents, cancer vaccines, and chemotherapy across multiple indications such as melanoma, pancreatic cancer and other malignancies. For more information, visit www.newlinkgenetics.com , and follow us on Twitter @NLNKGenetics .\nInvestor Contact:\nLisa Miller\nDirector of Investor Relations\nNewLink Genetics\n(515) 598-2555\nlmiller@linkp.com\nMedia Contact:\nSharon Correia\nVP, Integrated Communications\nLaVoieHealthScience\n617-374-8800, ext. 105\nscorreia@lavoiehealthscience.com\nSource:NewLink Genetics Corporation",
    "published": "2018-02-16T17:00:00.000+02:00",
    "crawled": "2018-02-16T18:27:58.016+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "ames",
        "iowa",
        "globe",
        "newswire",
        "newlink",
        "genetics",
        "corporation",
        "nasdaq",
        "nlnk",
        "today",
        "announced",
        "release",
        "fourth",
        "quarter",
        "year",
        "end",
        "financial",
        "result",
        "thursday",
        "march",
        "company",
        "scheduled",
        "conference",
        "call",
        "pm",
        "et",
        "day",
        "discus",
        "result",
        "give",
        "update",
        "clinical",
        "business",
        "development",
        "activity",
        "newlink",
        "genetics",
        "senior",
        "management",
        "team",
        "host",
        "conference",
        "call",
        "open",
        "listener",
        "also",
        "question",
        "answer",
        "session",
        "following",
        "prepared",
        "remark",
        "access",
        "live",
        "call",
        "available",
        "dialing",
        "international",
        "five",
        "minute",
        "prior",
        "start",
        "call",
        "conference",
        "call",
        "webcast",
        "live",
        "link",
        "accessed",
        "newlink",
        "genetics",
        "website",
        "http",
        "replay",
        "call",
        "available",
        "two",
        "week",
        "date",
        "call",
        "accessed",
        "dialing",
        "international",
        "using",
        "passcode",
        "newlink",
        "genetics",
        "corporation",
        "newlink",
        "genetics",
        "biopharmaceutical",
        "company",
        "focusing",
        "discovering",
        "developing",
        "commercializing",
        "novel",
        "product",
        "candidate",
        "improve",
        "life",
        "patient",
        "cancer",
        "newlink",
        "genetics",
        "ido",
        "pathway",
        "inhibitor",
        "designed",
        "harness",
        "multiple",
        "component",
        "immune",
        "system",
        "combat",
        "cancer",
        "indoximod",
        "company",
        "leading",
        "ido",
        "inhibitor",
        "evaluated",
        "combination",
        "treatment",
        "regimen",
        "including",
        "agent",
        "cancer",
        "vaccine",
        "chemotherapy",
        "across",
        "multiple",
        "indication",
        "melanoma",
        "pancreatic",
        "cancer",
        "malignancy",
        "information",
        "visit",
        "follow",
        "u",
        "twitter",
        "nlnkgenetics",
        "investor",
        "contact",
        "lisa",
        "miller",
        "director",
        "investor",
        "relation",
        "newlink",
        "genetics",
        "lmiller",
        "medium",
        "contact",
        "sharon",
        "correia",
        "vp",
        "integrated",
        "communication",
        "lavoiehealthscience",
        "ext",
        "scorreia",
        "source",
        "newlink",
        "genetics",
        "corporation"
    ]
}